(Q71864060)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7606988%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

title

Inhaled salmeterol and albuterol in asthmatic patients receiving high-dose inhaled corticosteroids (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7606988%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

Inhaled Salmeterol and Albuterol in Asthmatic Patients Receiving High-dose Inhaled Corticosteroids (English)

1 reference

https://api.crossref.org/works/10.1378/CHEST.108.1.36

11 June 2024

1 reference

C. K. Lai

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7606988

11 June 2024

C. H. Chan

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7606988

11 June 2024

S. S. Ho

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7606988

11 June 2024

A. C. Hui

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7606988

11 June 2024

K. N. Lai

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7606988

11 June 2024

language of work or name

English

0 references

publication date

1 July 1995

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7606988%20AND%20SRC:MED&resulttype=core&format=json

full work available at URL

21 October 2019

https://api.elsevier.com/content/article/PII:S0012369216385889?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1378/CHEST.108.1.36

https://api.elsevier.com/content/article/PII:S0012369216385889?httpAccept=text/plain

11 June 2024

1 reference

https://api.crossref.org/works/10.1378/CHEST.108.1.36

11 June 2024

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7606988%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

volume

108

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7606988%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7606988%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

page(s)

36-40

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7606988%20AND%20SRC:MED&resulttype=core&format=json

Salmeterol, a novel, long-acting β2-adrenoceptor agonist: characterization of pharmacological activity in vitro and in vivo

21 October 2019

cites work

1

1 reference

https://api.crossref.org/works/10.1378/CHEST.108.1.36

Duration of Protection by Inhaled Salmeterol in Exercise-induced Asthma

11 June 2024

2

1 reference

https://api.crossref.org/works/10.1378/CHEST.108.1.36

Salmeterol, a new inhaled beta 2-adrenergic agonist, has a longer blocking effect than albuterol on hyperventilation-induced bronchoconstriction

11 June 2024

3

1 reference

https://api.crossref.org/works/10.1378/CHEST.108.1.36

A Single-dose Comparison of Inhaled Albuterol and Two Formulations of Salmeterol on Airway Reactivity in Asthmatic Subjects

11 June 2024

4

1 reference

https://api.crossref.org/works/10.1378/CHEST.108.1.36

Protection against allergen-induced asthma by salmeterol

11 June 2024

5

1 reference

https://api.crossref.org/works/10.1378/CHEST.108.1.36

A comparative study in atopic subjects with asthma of the effects of salmeterol and salbutamol on allergen-induced bronchoconstriction, increase in airway reactivity, and increase in urinary leukotriene E4 excretion

11 June 2024

6

1 reference

https://api.crossref.org/works/10.1378/CHEST.108.1.36

The effect of salmeterol on the early- and late-phase reaction to bronchial allergen and postchallenge variation in bronchial reactivity, blood eosinophils, serum eosinophil cationic protein, and serum eosinophil protein X

11 June 2024

7

1 reference

https://api.crossref.org/works/10.1378/CHEST.108.1.36

Inhaled salmeterol in the treatment of patients with moderate to severe reversible obstructive airways disease--a 3-month comparison of the efficacy and safety of twice-daily salmeterol (100 micrograms) with salmeterol (50 micrograms)

11 June 2024

9

1 reference

https://api.crossref.org/works/10.1378/CHEST.108.1.36

Inhaled salmeterol and salbutamol in asthmatic patients. An evaluation of asthma symptoms and the possible development of tachyphylaxis

11 June 2024

10

1 reference

https://api.crossref.org/works/10.1378/CHEST.108.1.36

A comparison of salmeterol with albuterol in the treatment of mild-to-moderate asthma

11 June 2024

11

1 reference

https://api.crossref.org/works/10.1378/CHEST.108.1.36

Twelve month comparison of salmeterol and salbutamol as dry powder formulations in asthmatic patients. European Study Group

11 June 2024

13

1 reference

https://api.crossref.org/works/10.1378/CHEST.108.1.36

Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment

11 June 2024

14

1 reference

https://api.crossref.org/works/10.1378/CHEST.108.1.36

International Consensus Report on Diagnosis and Treatment of Asthma

11 June 2024

15

1 reference

https://api.crossref.org/works/10.1378/CHEST.108.1.36

Guidelines on the management of asthma

11 June 2024

16

1 reference

https://api.crossref.org/works/10.1378/CHEST.108.1.36

Prescribed fenoterol and death from asthma in New Zealand, 1981-83: case-control study

11 June 2024

17

1 reference

https://api.crossref.org/works/10.1378/CHEST.108.1.36

Case-control study of prescribed fenoterol and death from asthma in New Zealand, 1977-81

11 June 2024

18

1 reference

https://api.crossref.org/works/10.1378/CHEST.108.1.36

Regular inhaled beta-agonist treatment in bronchial asthma.

11 June 2024

19

1 reference

https://api.crossref.org/works/10.1378/CHEST.108.1.36

The use of beta-agonists and the risk of death and near death from asthma

11 June 2024

20

1 reference

https://api.crossref.org/works/10.1378/CHEST.108.1.36

Rebound increase in bronchial responsiveness after treatment with inhaled terbutaline

11 June 2024

21

1 reference

https://api.crossref.org/works/10.1378/CHEST.108.1.36

Use of exercise challenge to investigate possible tolerance to beta-adrenoceptor stimulation in asthma

11 June 2024

22

1 reference

https://api.crossref.org/works/10.1378/CHEST.108.1.36

Long-term effects of a long-acting beta 2-adrenoceptor agonist, salmeterol, on airway hyperresponsiveness in patients with mild asthma

11 June 2024

23

1 reference

https://api.crossref.org/works/10.1378/CHEST.108.1.36

Tolerance to the nonbronchodilator effects of inhaled beta 2-agonists in asthma

11 June 2024

24

1 reference

https://api.crossref.org/works/10.1378/CHEST.108.1.36

Regular inhaled salbutamol and airway responsiveness to allergen

11 June 2024

25

1 reference

https://api.crossref.org/works/10.1378/CHEST.108.1.36

The effect of an increase in inhaled allergen dose after rimiterol hydrobromide on the occurrence and magnitude of the late asthmatic response and the associated change in nonspecific bronchial responsiveness

11 June 2024

26

1 reference

https://api.crossref.org/works/10.1378/CHEST.108.1.36

Salmeterol: a potent and long-acting inhibitor of inflammatory mediator release from human lung

11 June 2024

27

1 reference

https://api.crossref.org/works/10.1378/CHEST.108.1.36

One explanation of the asthma paradox: inhibition of natural anti-inflammatory mechanism by beta 2-agonists

11 June 2024

29

1 reference

https://api.crossref.org/works/10.1378/CHEST.108.1.36

Effects of inhaled heparin on immunologic and nonimmunologic bronchoconstrictor responses in sheep

11 June 2024

30

1 reference

https://api.crossref.org/works/10.1378/CHEST.108.1.36

Soluble markers of allergic inflammation

11 June 2024

31

1 reference

https://api.crossref.org/works/10.1378/CHEST.108.1.36

Serum concentration of soluble interleukin 2 receptors in asthma. Correlation with disease activity

11 June 2024

32

1 reference

https://api.crossref.org/works/10.1378/CHEST.108.1.36

Heparin inhibits the immediate response to antigen in the skin and lungs of allergic subjects

11 June 2024

39

1 reference

https://api.crossref.org/works/10.1378/CHEST.108.1.36

Preventing bronchoconstriction in exercise-induced asthma with inhaled heparin

11 June 2024

40

1 reference

https://api.crossref.org/works/10.1378/CHEST.108.1.36

Histamine-induced suppressor-cell activity

11 June 2024

41

1 reference

https://api.crossref.org/works/10.1378/CHEST.108.1.36

Modulation of cellular immune function in vitro by histamine receptor-bearing lymphocytes: Mechanism of action

11 June 2024

43

1 reference

https://api.crossref.org/works/10.1378/CHEST.108.1.36

Is inhibition of mast cell mediator release relevant to the clinical activity of anti-allergic drugs?

11 June 2024

46

1 reference

https://api.crossref.org/works/10.1378/CHEST.108.1.36

The inhibitory effect of nebulized albuterol on the early and late asthmatic reactions and increase in airway responsiveness provoked by inhaled allergen in asthma

11 June 2024

48

1 reference

https://api.crossref.org/works/10.1378/CHEST.108.1.36

11 June 2024

Identifiers

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7606988%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

1 reference